Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the publication of foundational preclinical data in Cell ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemons ...

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.

Hengrui, one of China's leading pharmaceutical companies, is preparing to bring its cancer therapies to international markets ...

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&GreenCNS ...

As we move into the final stretch of the year, stocks continue to grind higher, with the S&P 500 now up 16% year-to-date. Once again, it’s Big Tech leading the charge – the mega-cap innovators ...

Triple-negative breast cancer is one of the most aggressive and difficult cancers to treat. It can initially respond well to ...

Virginia Giuffre’s memoir 'Nobody’s Girl' details her trauma involving Jeffrey Epstein I've been a recruiter for 38 years.

A cellular resistance mechanism at the origin of relapses of triple-negative breast cancer has recently been discovered by ...

Last November, Marcela Tinka received devastating news: she was diagnosed with triple-negative breast cancer, a fast-moving form that affects about 10% to 15% of breast cancer patients.